NASDAQ · LEGN
Legend Biotech financials
$18.82+1.07%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $1.03B | $627.3M | $285.1M | $117.0M | $68.8M |
| Gross profit | $620.8M | $392.7M | $140.9M | $51.6M | $68.8M |
| Gross margin | 60.3% | 62.6% | 49.4% | 44.1% | 100.0% |
| Operating income | -$136.5M | -$309.5M | -$528.1M | -$434.9M | -$400.1M |
| Net income | -$296.8M | -$177.0M | -$518.3M | -$446.3M | -$403.6M |
| Net margin | −28.8% | −28.2% | −181.8% | −381.5% | −586.4% |
| Diluted EPS | $-0.81 | $-0.48 | $-1.47 | $-1.40 | $-1.43 |
| EBITDA | -$127.1M | -$298.8M | -$517.4M | -$422.3M | -$390.6M |
| Operating cash flow | -$100.2M | -$144.0M | -$393.3M | -$201.3M | -$198.5M |
| Free cash flow | -$167.6M | -$213.0M | -$512.2M | -$222.2M | -$240.7M |
| Diluted shares | 368.6M | 365.7M | 352.2M | 318.1M | 282.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $901.9M | $286.7M | $1.28B | $786.0M |
| Short-term investments | $0.00 | $0.00 | $663.0K | $185.6M |
| Total debt | $319.1M | $301.2M | $281.3M | $260.9M |
| Total assets | $1.73B | $1.67B | $1.85B | $1.33B |
| Total liabilities | $731.6M | $629.6M | $597.2M | $586.7M |
| Shareholders' equity | $1.00B | $1.04B | $1.25B | $744.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology